Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAPK1 | P53355 | 1/20 | 0.32 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22650743 | 0.78 | DAPK1 (0.33) | DAPK1DCTPP1CDK1CDK4CCNB1 | |
| SCHEMBL29491180 | 0.78 | DAPK1 (0.33) | DAPK1DCTPP1CDK1CDK4CCNB1 | |
| SCHEMBL22650391 | 0.71 | JAK2 (0.32) | — | |
| SCHEMBL22650827 | 0.69 | CDK4 (0.39) | DAPK1CDK1CDK4CCNB1CCND1 | |
| SCHEMBL22650829 | 0.68 | CDK4 (0.34) | CDK1CDK4CCNB1CCND1 | |
| SCHEMBL22650828 | 0.68 | CDK4 (0.33) | CDK1CDK4CCNB1CCND1 | |
| SCHEMBL22650826 | 0.66 | AAK1 (0.38) | CDK1CDK4CCNB1CCND1 | |
| SCHEMBL22650586 | 0.66 | EGFR (0.39) | CDK1CDK4CCNB1CCND1 | |
| SCHEMBL26521402 | 0.65 | SQOR (0.35) | — | |
| SCHEMBL23598167 | 0.64 | DCTPP1 (0.39) | DAPK1DCTPP1CDK1CDK4CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040446-A | CDK inhibitors | 基因泰克公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | DAPK1 1133/4885DCTPP1 570/4885CDK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.